THE SIGNIFICANCE OF VASPIN AND OMENTIN IN THE DE VELOPMENT OF OBESIT Y — A PREDICTOR OF CARDIOVASCUL AR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES

Authors

  • Kravchun N. A. SI «V. Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine», Kharkiv, Ukraine
  • Alhamid M. H. SI «V. Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine», Kharkiv, Ukraine
  • Misyura K. V. SI «V. Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine», Kharkiv, Ukraine
  • Dunaieva I. P. Kharkiv National Medical University, Kharkiv, Ukraine
  • Romanova I. P. SI «V. Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine», Kharkiv, Ukraine
  • Chernyavska I. V. SI «V. Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine», Kharkiv, Ukraine
  • Sokolova S. S. SI «V. Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2021.1.05

Keywords:

vaspin, omentin, type 2 diabetes mellitus, obesity, cardiovascular diseases.

Abstract

The aim of the work was to find out the significance of vaspin and omentin in metabolic shifts, endothelial dysfunction, cardiovascular diseases and other vascular disorders in patients with type 2 diabetes mellitus based on the analysis of modern literature sources and their own research. Material and methods. A thorough review of modern literature sources, including the results of clinical and experimental data, on studies of the importance of the hormones vaspin and omentin in the development of cardiovascular complications in patients with type 2 diabetes mellitus against the background of obesity, was carried out. 75 patients with type 2 diabetes mellitus, overweight and obese of varying degrees were examined. Serum vaspin and omentin levels were determined. The presence and strength of the relationship between factors were calculated using the Spearman — rs rank correlation coefficient. As a result of the analysis of literature data, it was found that at the present stage, the biological and pathophysiological effects of vaspin and omentin in the human body are not fully clarified, and data on their prognostic and diagnostic value in patients with type 2 diabetes mellitus with cardiovascular pathology against the background of obesity are extremely small, so when studying their own data on finding out the role of these adipokines in the development of metabolic disorders, namely, obesity of varying degrees, as a predictor of cardiovascular complications in the above patients, the inverse correlation of vaspin with waist circumference indicators is proved, fat mass and body mass index and straight-with the outline of the hips. As for omentin, data were obtained that indicate the presence of a direct correlation between this adipokin and waist circumference, fat mass and body mass index, the opposite — with hip circumference. It has also been suggested that these adipokines can be used as prognostic markers of cardiovascular complications in the above individuals. It is concluded that vaspin and omentin play an important role in the development of metabolic disorders, but require further research.

References

Bray G. A. J Clin Endocrinol Metab 2004; 89: 2583-2589. https://doi.org/10.1210/jc.2004-0535.

Rabe K, Lehrke M, Parhofer KG, et al. Mol Med 2008; 14: 741-751. https://doi.org/10.2119/2008-00058.Rabe.

Flehmig G, Scholz M, Klöting N, et al. PLoS One 2014; 9: e99785. https://doi.org/10.1371/journal.pone.0099785.

Guvenc Y, Var A, Goker A, et al. J Int Med Res 2016; 44: 796-805. https://doi.org/10.1177/0300060516645421.

Klöting N, Berndt J, Kralisch S, et al. Biochem Biophys Res Commun 2006; 339: 430-436. https://doi.org/10.1016/j.bbrc.2005.11.039.

Hida K, Wada J, Eguchi J, et al. Proc Natl Acad Sci USA 2005; 102: 10610-10615. https://doi.org/10.1073/pnas.0504703102.

Youn BS, Klöting N, Kratzsch J, et al. Diabetes 2008; 57: 372-377. https://doi.org/10.2337/db07-1045.

Suleymanoglu S, Tascilar E, Pirgon O, et al. Diabetes Res Clin Pract 2009; 84: 325-328. https://doi.org/10.1016/j.diabres.2009.03.008.

Saalbach A, Tremel J, Herbert D, et al. Am J Pathol 2016; 186: 639-651. https://doi.org/10.1016/j.ajpath.2015.10.030.

Li HL, Peng WH, Cui ST, et al. Clin Chem Lab Med 2011; 49: 1547-1554. https://doi.org/10.1515/CCLM.2011.236.

Villareal DT, Chode S, Parimi N, et al. N Engl J Med 2011; 364: 1218-1229. https://doi.org/10.1056/NEJMoa1008234.

Fasshauer M, Bluher M. Trends Pharmacol Sci 2015; 36:461-470. https://doi.org/10.1016/j.tips.2015.04.014.

Wada J. Rinsho Byori 2008; 56: 705-711.

Hao F, Zhang H, Zhu J, et al. Diabetes Res Clin Pract 2016;113: 26-32. https://doi.org/10.1016/j.diabres.2015.12.001.

Misjura KV, Kravchun PP. Mizhnar Endokrynol Zhurn 2017; 13(4): 22-27. https://doi.org/10.22141/2224-0721.13.4.2017.106648.

Dalia H. El-Lebedy, Alshaymaa A I., Ashmawy I. O. Diabetes Metab Syndr 2018; 12(5): 643-648. https://doi.org/10.1016/j.dsx.2018.04.025.

Pan HY, Guo L, Li Q. Diabetes Res Clin Pract 2010; 88: 29-33. https://doi.org/10.1016/j.diabres.2010.01.013.

Tan BK, Adya R, Farhatullah S, et al. Diabetes 2008; 57: 801-808. https://doi.org/10.2337/db07-0990.

de Souza Batista CM, Yang RZ, Lee MJ, et al. Diabetes 2007; 56: 1655-1661. https://doi.org/10.2337/db06-1506.

Yan P, Liu D, Long M, et al. R Li Exp Clin Endocrinol Diab 2011; 119: 257-263. https://doi.org/10.1055/s-0030-1269912.

Xu T, Zuo P, Cao L, et al. Thromb J 2018; 25(6): 505-511. https://doi.org/10.5551/jat.42135.

Escoté X, Gómez-Zorita S, López-Yoldi M, et al. Int J Mol Sci 2017; 18(8): 1770. https://doi.org/10.3390/ijms18081770.

Yoo HJ, Hwang SY, Hong HC, et al. Diabetology 2011; 10: 103. https://doi.org/10.1186/1475-2840-10-103.

Misjura KV, Kravchun PP. Klinichna endokrynologija ta endokrynna hirurgija 2017; 3(59): 60-68. https://doi.org/10.24026/1818-1384.3(59).2017.110906.

Ji-Yin Zhou, Lawrence Chan, Shi-Wen Zhou Curr. Vasc Pharmacol 2014; 12(1): 136-143. https://doi.org/10.2174/1570161112999140217095038.

Kravchun PG, Kravchun PP. Medicina 2015; 1(151): 5-9, http://repo.knmu.edu.ua/handle/123456789/9046.

Shibata R, Ouchi N, Kikuchi R, et al. Atherosclerosis 2011; 219: 811-814. https://doi.org/10.1016/j.atherosclerosis. 2011.08.017.

Zhong X, Zhang HY, Tan H, et al. Acta Pharmacol Sin 2011; 32: 873-878. https://doi.org/10.1038/aps.2011.26.

Kadoglou NP, Lambadiari V, Gastounioti A, et al. Atherosclerosis 2014; 235: 606-612. https://doi.org/10.1016/j.atherosclerosis.2014.05.957.

Moreno-Navarrete JM, Ortega F, Castro A, et al. Obesity 2011; 19(8): 1552-1559. https://doi.org/10.1038/oby.2010.351.

Shibata R, Takahashi R, Kataoka Y, et al. Hypertens Res 2011; 34: 1309-1312. https://doi.org/10.1038/hr.2011.130.

Hayashi M, Morioka T, Hatamori M, et al. Clin Pract 2019; 148: 160-168. https://doi.org/10.1016/j.diabres.2019.01.009.

Maruyama S, Shibata R, Kikuchi R, et al. J Biol Chem 2012; 287: 408-417. https://doi.org/10.1074/jbc.M111.261818.

Wang Y, Sun M, Wang Z, et al. Biophys Res Commun 2018; 498: 152-156. https://doi.org/10.1016/j.bbrc.2018.02.012.

Yamawaki H, Tsubaki N, Mukohda M, et al. Res Commun 2010; 393: 668-672. https://doi.org/10.1016/j.bbrc.2010.02.053.

Uemura Y, Shibata R, Kanemura N, et al. FASEB J 2015; 29: 141-151. https://doi.org/10.1096/fj.14-258129.

Hiramatsu-Ito M, Shibata R, Ohashi K, et al. Cardiovasc Res 2016; 110: 107-117. https://doi.org/10.1093/cvr/cvv282.

Kataoka Y, Shibata R, Ohashi K, et al. J Am Coll Cardiol 2014; 63: 2722-2733. https://doi.org/ 10.1016/j.jacc.2014.03.032.

Garvey W, Garber AJ, Mechanick JI, et al. Endocr Pract 2014; 20(9): 977-989. https://doi.org/10.4158/EP14280.PS.

World Health Organization. Obesity and Overweight. Factsheet. WHO Media Centre, available at: https://www.who.int/ru/news-room/fact-sheets/detail/obesityand-overweight

Downloads

Published

2021-03-03

How to Cite

Кравчун, Н. О., Алхамід, М. Х., Місюра, К. В., Дунаєва, І. П., Романова, І. П., Чернявська, І. В., & Соколова, С. С. (2021). THE SIGNIFICANCE OF VASPIN AND OMENTIN IN THE DE VELOPMENT OF OBESIT Y — A PREDICTOR OF CARDIOVASCUL AR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES. Problems of Endocrine Pathology, 75(1), 34-42. https://doi.org/10.21856/j-PEP.2021.1.05

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 5 6 > >>